Men now receive over half a million neuromodulator injections per year in the United States. ASPS data for 2024 records 593,854 botulinum toxin procedures performed on men, representing approximately 6% of all neuromodulator treatments. The ISAPS 2023 global survey puts male participation even higher, at 14.5% of all non-surgical cosmetic procedures. The male aesthetic market is projected to reach nearly $7 billion by 2026, and the broader men's grooming market is expected to exceed $90 billion by 2030. "Brotox" is no longer a punchline. It is a growing segment driven by workplace competitiveness, social media visibility, and a cultural shift in how men relate to appearance maintenance.
The problem is that most neuromodulator injection protocols, dosing guidelines, and training curricula were developed on female facial anatomy. The FDA label for glabellar lines — 20 units across five injection points — was established in pivotal trials where women outnumbered men by a wide margin. A 2020 systematic review by Roman and Zampella found that men represented only 13.9% of all randomized controlled trial participants for cosmetic botulinum toxin studies. The evidence base for male dosing is thinner than it should be, and it shows in the results: overtreated foreheads, feminized brow arches, and a "frozen" appearance that is more socially costly for men than for women.
This article is specifically about how male facial anatomy differs, what those differences mean for dosing and injection technique, and how the feminization risk can be avoided. It does not re-cover general neuromodulator anatomy or dosing philosophy — the site's article on natural-looking Botox addresses those topics in depth.
Male facial anatomy is genuinely different
The differences are not subtle, and they are not cosmetic preferences. They are structural.
Muscle size and strength. Male facial muscles are approximately 15–20% larger and more developed than female facial muscles, driven by lifelong androgen exposure. The frontalis — the broad sheet that elevates the brow and creates horizontal forehead lines — extends higher into the hairline in men and is stronger in its superior portion. The glabella muscles (corrugator supercilii and procerus) are typically thicker and generate more force. This means the same number of botulinum toxin units that adequately relaxes a female corrugator may produce only partial relaxation in a male one.
Brow position. This is the single most important anatomical difference for injection planning. Male eyebrows naturally sit at or near the orbital rim, running relatively straight across with at most a very slight lateral elevation. Female eyebrows arch several millimeters above the orbital rim, with the peak at the lateral limbus. Treating the male brow as if it were a female brow — creating or allowing an arch — is the most common injection error in male patients and the one most likely to produce a feminized appearance.
Skin thickness. Male skin is approximately 25% thicker than female skin, with higher collagen density and a different fat distribution pattern. Thicker skin dampens the visual effect of a given degree of muscle relaxation: lines may appear less softened even when the underlying muscle is partially treated, which tempts injectors to add more units than the muscle actually requires. The 2017 consensus panel led by Hexsel et al. emphasized that skin thickness must be factored into injection depth and dose, not just into expected cosmetic outcome.
Frontalis divergence. The point where the two halves of the frontalis muscle separate is generally lower in men. This changes where the muscle is active and where injection points should be placed. A standard five-point forehead pattern designed for a female frontalis divergence may miss the zones of maximum activity in a male forehead.
Expression patterns. Men tend to recruit different muscle patterns during facial expression. Male frowning often engages a wider band of corrugator activity, and male brow-raising creates broader forehead contraction. These patterns are visible during assessment — but only if the provider is looking for them rather than applying a one-size-fits-all injection map.
Men need more units, and the evidence base is thin
A 2024 analysis in the Aesthetic Surgery Journal reported that men require an average of 25–40% higher botulinum toxin doses for comparable muscle relaxation. This is not surprising given the muscle mass differences described above, but the precision of the range is misleading — it represents a population average across a small number of studies, most of which were not designed specifically to answer the male-dosing question.
A post-hoc analysis of prabotulinumtoxinA trials published in PMC in 2022 found that onabotulinumtoxinA efficacy in men was 13.1% lower across all study visits compared to the overall treated population. The implication is not that the product works less well in men — it is that the standard dose is insufficient for male muscle mass. The muscle is bigger; the same dose produces less relaxation; the patient gets a weaker result.
Approximate dosing comparisons, drawn from clinical literature and expert consensus rather than from FDA labels (which specify single doses, not sex-adjusted ranges):
Glabella. The FDA label specifies 20 units. In practice, many women receive 16–20 units for satisfactory glabellar relaxation. Men more commonly require 30–40 units for comparable effect. The Allergan high-dose study provides supporting data: 40 units in the glabella produced a 32% responder rate at week 24, and 80 units produced a 38.5% responder rate — compared to 16% for the standard 20-unit dose. The higher doses were safe and well tolerated. This does not mean every man needs 40–80 units in the glabella. It means the 20-unit standard was established in predominantly female trials and should not be treated as a ceiling for male patients.
Forehead. Women typically receive 10–20 units. Men commonly require 20–30 units, though forehead dosing is particularly sensitive because over-treatment here is what causes brow ptosis and the mask-like frozen appearance that male patients find most objectionable.
Crow's feet. Women typically receive 12–24 units total (6–12 per side). Men commonly require 16–30 units total. The key concern in this area is not just dose but shape — over-treatment can create an artificially smooth orbital area that reads as cosmetically treated, even when the dose was technically appropriate.
The critical caveat: dose depends on individual patient anatomy, treatment goals, and provider judgment. There is no universal male dose. A 140-pound man with fine dynamic lines needs a different approach than a 220-pound man with deep static wrinkles and a broad, powerful frontalis. The evidence base is not thick enough to support a fixed male dosing table, and any provider who offers one is extrapolating beyond the data.
The feminization risk and how it happens
The most recognizable sign that a man has had Botox is not a smooth forehead. It is an arched brow.
An arched brow is a feminine secondary sexual characteristic. When a male brow arches above the orbital rim — particularly when the peak sits at the lateral limbus, as it does in the classical female brow aesthetic — the result reads as feminized. It does not read as "youthful" or "refreshed." It reads as "had work done," and it is the single result male patients find most distressing.
The arch happens through a specific mechanism: over-relaxation of the central and superior frontalis while leaving the lateral frontalis (the temporal portion) untreated or under-treated. The central frontalis elevates the medial brow. If the lateral frontalis — which elevates the lateral brow — is weakened more than the medial portion, or if the lateral brow depressors (the orbital portion of the orbicularis oculi) are treated without balancing the lateral frontalis, the lateral brow elevates disproportionately. The result is an arch.
To prevent this:
Inject centrally and superiorly in the frontalis. Keep injections in the upper portion of the forehead, at least 1.5–2 cm above the orbital rim. Leave the lateral frontalis (the temporal portion near the brow tail) untreated or significantly under-treated to preserve natural lateral brow movement.
Do not over-treat the lateral brow depressors. The orbicularis oculi near the lateral brow is a depressor — it pulls the brow down. Treating it removes a downward force, which elevates the brow. In women, this lateral elevation is often a desired effect. In men, it is the primary driver of the feminized arch. Conservative treatment of the lateral orbicularis, or avoidance of treatment in this area entirely, preserves the male brow position.
Keep the brow at or near the orbital rim. The male brow should remain straight or have very slight lateral elevation. Any arch — even a subtle one — is visible in professional and social contexts in a way that a flat brow with softened lines is not.
Avoid the frozen forehead. Over-treating the entire frontalis creates a heavy, static, mask-like appearance that is more noticeable on men because male facial expressions tend to be broader and more dynamic in professional contexts. A man who cannot furrow his brow during a meeting or raise his eyebrows in conversation appears unnatural in a way that draws more attention than the lines ever did. The "Spock brow" or "Jack Nicholson" effect — where uneven relaxation causes one portion of the brow to shoot up while the rest stays flat — is a specific variant of this problem caused by inconsistent injection depth or spacing across the frontalis.
Injection technique for male anatomy
The adjustments are not arbitrary. They follow from the anatomy.
Deeper injections. Male skin is thicker and male muscles are larger. Injections that would reach the target muscle in a female patient may deposit toxin in the subcutaneous tissue of a male patient, where it diffuses ineffectively. Deeper placement — often to the mid-muscle belly rather than the subcutaneous-muscle interface — is frequently necessary.
Glabella. Men typically receive 4–6 units per injection point (compared to 4 per point in the standard female protocol), distributed across five or more points. Men with wide corrugator patterns may need additional injection points to cover the full width of muscle activity. The total commonly falls between 30 and 40 units. As with all areas, the injection pattern should be determined by palpation and by watching the patient frown, not by applying a template.
Forehead. Injection points should be at least 1.5–2 cm above the orbital rim to prevent brow ptosis. In men, the frontalis divergence is lower, so the standard two-row pattern used in many training protocols may need to shift superiorly. Spacing between injection points should be approximately 1.5 cm, which corresponds roughly to the diffusion radius of reconstituted toxin — closer spacing creates overlap and wider paralysis than intended, while wider spacing leaves gaps in coverage.
Crow's feet. The goal is to soften radial lines while preserving the masculine orbital shape. Over-treatment here creates an artificially smooth eye area that is immediately recognizable as cosmetically treated. Conservative dosing — starting at the lower end of the male range and adding at a two-week follow-up — is safer than front-loading the maximum dose.
Brow. Conservative treatment is the rule. The lower male brow is a natural feature, not a defect to correct. Injectors who attempt to "open up" the male brow by weakening the depressors are often creating the feminization problem this article is about. The male brow should stay where it is; the goal is to soften the lines around it, not to elevate it.
What men actually want and what they fear
The typical male patient's goals are narrower than the typical female patient's goals, and the fear profile is different.
Most men who seek neuromodulator treatment want to look rested, not treated. The most common request, in the experience of providers who treat significant numbers of men, is some version of "I want people to think I slept well, not that I got Botox." The implication is clear: the acceptable outcome is a subtle improvement that could plausibly be attributed to rest, skincare, or genetics. The unacceptable outcome is one that is identifiable as a cosmetic procedure.
The "frozen" look is a bigger fear for men than for women, and for practical reasons. Men in professional settings — negotiations, leadership meetings, client-facing roles — cannot afford to look expressionless. A face that does not move during a conversation reads as disengaged, untrustworthy, or odd. This is not vanity; it is professional self-preservation. The provider who understands this treats conservatively.
Men also tend to prefer fewer visits and longer intervals between treatments — a "maximum impact, minimal follow-up" strategy. This preference creates a tension with conservative dosing, because conservative doses wear off faster. Some men accept this tradeoff and return more frequently with smaller adjustments. Others push for higher doses to stretch the interval, accepting somewhat more movement reduction in exchange for fewer clinic visits. The provider's job is to explain the tradeoff clearly and let the patient choose, not to assume that every male patient wants the same balance.
Hyperhidrosis treatment has emerged as an important entry point. Botox for excessive sweating — typically axillary (underarm), sometimes palmar (hand) or plantar (foot) — has more than doubled among men between 2022 and 2024. For many male patients, this is their first experience with botulinum toxin. A positive hyperhidrosis outcome often opens the conversation about cosmetic treatment, and providers who recognize this pathway can introduce facial treatment in a way that feels clinical rather than cosmetic, which lowers the barrier for male patients who are ambivalent about aesthetic procedures.
Choosing a provider who knows male anatomy
Not all injectors have equal experience with male faces. The differences described in this article — muscle mass, brow position, skin thickness, frontalis divergence — are not subtle, but they are also not part of most standard injection training, which uses female anatomy as the default model. A provider who has treated hundreds of women and fewer than a dozen men may be technically skilled but anatomically unprepared for the differences.
Questions worth asking:
"How many men do you treat regularly?" This is a reasonable question, and the answer should be more than "a few." A provider whose practice is 95% female may not have the pattern-recognition experience to spot the early signs of brow arch or over-treatment that are specific to male anatomy.
"What is your approach to preserving masculine brow position?" If the provider's answer does not specifically mention leaving the lateral frontalis untreated, avoiding over-treatment of the lateral orbicularis oculi, and keeping the brow at the orbital rim, they may not have a systematic approach to the feminization risk.
"Will you start conservatively and add more at a follow-up if needed?" The "start low, add more" approach is safer for every patient, but it is especially important for men because the consequences of over-treatment are more visible and more socially costly. A provider who maximizes dose on the first visit is eliminating the option for a controlled adjustment.
Board-certified dermatologists and plastic surgeons with specific experience treating male patients are the strongest choices, because their training includes detailed facial anatomy and their practices typically see enough male patients to develop pattern recognition for the differences described here. Nurse practitioners and physician assistants can be excellent injectors for male patients, but should have a track record of male-specific treatment and be working under the supervision of a physician who reviews treatment plans.
Product choice matters less than injector knowledge
All FDA-approved neuromodulators — Botox (onabotulinumtoxinA), Dysport (abobotulinumtoxinA), Xeomin (incobotulinumtoxinA), Jeuveau (prabotulinumtoxinA), and Daxxify (daxibotulinumtoxinA) — can be used in men. None has a specific FDA indication for male patients, and none has a male-specific dosing recommendation on its label. The choice of product matters far less than the injector's knowledge of male anatomy and their willingness to adjust dose, depth, and injection pattern accordingly.
Botox Cosmetic has the longest clinical track record in men and is the product for which the most male-specific data exists, including the high-dose glabellar study cited above. Xeomin received FDA approval for both forehead lines and crow's feet in July 2024, making it the first neuromodulator besides Botox fully approved for all major upper-facial wrinkle areas. Daxxify may offer longer duration, which appeals to men who prefer fewer clinic visits, but male-specific duration data is still limited — the pivotal trials were not designed to answer that question.
The bottom line: a provider who understands male facial anatomy will get a good result with any of these products. A provider who does not understand male facial anatomy will get a mediocre or feminized result with any of these products. Product selection is a secondary decision.
Sources
ASPS. "2024 Cosmetic Surgery Procedures — Gender Distribution (Male)." https://www.plasticsurgery.org/documents/news/statistics/2024/cosmetic-procedures-men-2024.pdf
PrabotulinumtoxinA vs OnabotulinumtoxinA for the Treatment of Adult Males With Moderate to Severe Glabellar Lines: Post-hoc Analyses. PMC. 2022. https://pmc.ncbi.nlm.nih.gov/articles/PMC9750667/
Allergan. "Higher Dose BOTOX Cosmetic for Moderate to Severe Glabellar Lines." https://www.prnewswire.com/news-releases/allergan-announces-results-of-higher-dose-botox-cosmetic-onabotulinumtoxina-for-the-treatment-of-moderate-to-severe-glabellar-lines-300713102.html
Hexsel D, et al. "Tailored botulinum toxin type A injections in aesthetic medicine: consensus panel recommendations for treating the forehead based on individual facial anatomy and muscle tone." PMC. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5655032/
NCTCS. "Botulinum Toxin Treatment of the Upper Face." StatPearls/NCBI. https://www.ncbi.nlm.nih.gov/books/NBK574523/
BOTOX Cosmetic Prescribing Information. FDA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/103000s5306lbl.pdf
BOTOX Cosmetic Dosing and Injection Guide. AbbVie/Allergan. https://www.botoxcosmetichcp.com/content/dam/hcp-botox-cosmetic/documents/The%20one%20and%20only%20Dosing%20and%20Injection%20Guide.pdf
BOTOX Cosmetic FDA Approval for Forehead Lines. September 2017. https://www.prnewswire.com/news-releases/fda-approves-botox-cosmetic-onabotulinumtoxina-for-the-temporary-improvement-in-the-appearance-of-moderate-to-severe-forehead-lines-associated-with-frontalis-muscle-activity-in-adults-300529648.html
